Are we Missing Barrett’s Esophagus in Our Busy Endoscopy Practice? Improving Detection

Amit Kumar Dutta¹

¹Department of Gastrointestinal Sciences, Christian Medical College and Hospital, Vellore, Tamil Nadu, India

Address for correspondence Amit Kumar Dutta, MD, DM, Department of Gastrointestinal Sciences, Christian Medical College and Hospital, Vellore 632004, Tamil Nadu, India (e-mail: akdutta1995@gmail.com).

Abstract

Barrett’s esophagus (BE) denotes the replacement of stratified squamous epithelium of esophagus by columnar epithelium. It is associated with a significantly increased risk of esophageal adenocarcinoma and hence patients with BE are advised endoscopic surveillance for early detection of dysplastic and neoplastic lesions. Esophageal cancer is the sixth most common cancer in terms of incidence and mortality in India. Around 15 to 25% of esophageal cancers are adenocarcinoma. BE is likely to be an important precursor of esophageal adenocarcinoma and we may be missing patients with BE in our busy endoscopy practice. The detection of BE may be improved by identifying high-risk groups, performing thorough endoscopic examination, and applying newer imaging techniques. The high-risk group includes patients with chronic gastroesophageal reflux disease, obesity, smoking, etc. During endoscopic examination, a careful assessment of the gastroesophageal junction and identification of important landmarks such as gastroesophageal junction and Z line are essential to detect BE.

Management of BE depends on the detection of dysplasia and for this four quadrant mucosal biopsy is recommended every 1 to 2 cm. However, random biopsy samples only a small area of mucosa and advanced technologies for real-time detection of dysplasia and neoplasia may overcome this limitation. In this review, we discuss the current scenario of BE in India and ways to improve the detection of BE including dysplastic lesions.

Keywords

► Barrett’s esophagus
► dysplasia
► image enhanced endoscopy
► risk factors

Introduction

The esophageal mucosa is lined by stratified squamous epithelium. Barrett’s esophagus (BE) is characterized by the replacement of the stratified squamous epithelium by columnar epithelium.¹ The columnar metaplasia may be intestinal or gastric type. In countries such as the USA, BE is diagnosed only in the presence of intestinal metaplasia (IM).² However, gastric metaplasia is also associated with neoplastic progression and in countries such as the UK, both gastric and intestinal columnar metaplasia are considered as BE.² The Indian Society of Gastroenterology Task Force on gastroesophageal reflux disease (GERD) has also endorsed the presence of gastric or intestinal metaplasia on histopathology as diagnostic of BE.³ The key factor predisposing to the development of BE is GERD. As BE may progress to dysplasia and adenocarcinoma in some patients, periodic surveillance is recommended to detect lesions at an early stage.

BE is associated with 30 to 40 times increased the risk of esophageal adenocarcinoma. Esophageal cancer is the sixth most common cancer in India and 15 to 25% of them are adenocarcinoma. The majority of them are locally advanced at the time of diagnosis. Considering the high prevalence of GERD, BE is likely to be an important precursor of esophageal adenocarcinoma among the Indian patients and we may be missing patients with BE in our busy endoscopy practice. There is a need for increased awareness and careful examination during endoscopy to improve the detection of BE.

**Barrett’s Esophagus in Indian Population**

Globally, the prevalence of BE is estimated to be between 0.6 and 1.1%. About 2 to 5% of patients undergoing upper gastrointestinal endoscopy have BE and this figure increases to 5 to 15% in those with GERD. The prevalence is higher in western countries. The annual rate of development of adenocarcinoma in BE is ~0.1 to 0.5%. The risk is higher in patients with dysplasia, especially high-grade dysplasia (HGD) and long segment BE.

BE is considered to be uncommon in the Asian region. However, a meta-analysis of 51 studies from the Asian countries estimated the pooled prevalence of endoscopic BE to be 7.8% (95% CI: 5–12.1%) and biopsy confirmed BE to be 1.3% (95% CI: 0.7–2.2%). The frequency of low-grade dysplasia (LGD) was 6.9%. Importantly, HGD was noted in 3% and esophageal adenocarcinoma (EAC) in 2%. The authors also noted a rising trend of BE in the last three decades. India had one of the highest frequencies of BE among the Asian countries. This has also been noted from a study on multi-ethnic population from Malaysia where the people of Indian origin were more frequently affected than the Malay and Chinese ethnic groups. Based on these observations, it is noted that BE is not uncommon among the Indian population, and the frequency of HGD and EAC among them is similar to that observed in the west.

Studies assessing the frequency of BE in India have shown a wide range from 2.6% to 23.6%. This may be due to differences in the definition of BE, target population, and study design. Table 1 summarizes the observations from the Indian studies. Patients with BE were usually in the 5th to 6th decades of life and men were affected two to four times more commonly than women. The frequency was noted to be higher in patients with GERD compared with unselected patients undergoing endoscopy or in patients with dyspepsia. In one of the studies, the presence of columnar metaplasia (gastric or intestinal) was noted in 16.54% of cases, while IM was noted in 8.99% of patients with GERD. In the same study, the median circumferential extent was 2 cm (1–10) and the median maximal extent was 3 cm (2–11). HGD/EAC and LGD were each noted in ~1% of subjects. As noted in other regions of the world, short-segment BE (extent up to 3 cm) is observed 6 to 8 times more frequently among the Indian patients than long-segment BE.

### Improving Detection of Barrett’s Esophagus

Considering the increasing frequency of BE observed in Indian studies, there is a need to improve awareness and detection. This includes the identification of high-risk individuals and endoscopic detection of BE. In addition, the management and outcome of BE depends on the identification of dysplasia. Several tools are available to improve the detection of dysplasia and their appropriate use may provide further benefit to the patients.

1) **Identifying high-risk group**: Multiple risk factors have been identified for BE. Among them, GERD is most important. Other risk factors include large hiatus hernia, obesity, older age, male gender, smoking, and family history of BE.

    a. **Gastroesophageal Reflux Disease**: The key factor in the development of BE is the reflux of acidic content from the stomach to the esophagus. Symptoms of GERD such as heartburn and regurgitation are present in ~55 to 60% of patients with BE. The prevalence of BE in GERD varies from 5 to 15% and this rises further in the presence of other risk factors. The risk of BE increases

<table>
<thead>
<tr>
<th>Study</th>
<th>Number of patients</th>
<th>Inclusion criteria</th>
<th>Columnar metaplasia</th>
<th>Specialized intestinal metaplasia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amrapurkar et al, 1998</td>
<td>150</td>
<td>Dyspepsia</td>
<td>4.7%</td>
<td>2.6%</td>
</tr>
<tr>
<td>Dhawan et al, 2001</td>
<td>271</td>
<td>Patients undergoing upper gastrointestinal endoscopy</td>
<td>6%</td>
<td></td>
</tr>
<tr>
<td>Punia et al, 2006,</td>
<td>55</td>
<td>GERD</td>
<td>23.6%</td>
<td>10.9%</td>
</tr>
<tr>
<td>Mathew et al, 2011</td>
<td>278</td>
<td>GERD</td>
<td>16.54%</td>
<td>8.99%</td>
</tr>
<tr>
<td>Wani et al, 2014</td>
<td>378</td>
<td>GERD</td>
<td>14.8%</td>
<td>2.38%</td>
</tr>
</tbody>
</table>
with the duration of GERD, especially after 5 years from the onset of symptoms. There are multiple studies from India, both community and hospital based, which have assessed the prevalence of GERD. A large community-based study from Vellore, evaluated 6,174 participants and the frequency of GERD was found to be 8.7\%. A multicenter hospital-based study by the Indian Society of Gastroenterology Task Force on GERD found the prevalence to be 7.6\%. Recently, a meta-analysis of studies on the prevalence of GERD in India estimated the pooled prevalence of this condition to be 15.6\% (11.1–20.1). These figures are not much lower than in the western countries. The significant burden of GERD in India and the high reported frequency of BE in GERD (\textit{Table 1}) suggests that this is an important target group for the detection of BE.

\textbf{b) Other risk factors:} BE is two to four times more common in men than women. Smoking almost doubles the risk of BE and obesity (abdominal or central obesity), the prevalence of which is rising in India, increases the risk to ~1.5 times. The presence of large hiatus hernia, older age (>50 years), white race, and family history of BE or EAC are other risk factors. The cumulative risk of BE increases by ~1.2\% with each additional risk factor.6

Guidelines for screening for BE in high-risk group: Considering the higher risk of BE in patients with GERD and other risk factors, various societies have made recommendations for screening. The British Society of Gastroenterology recommends screening in individuals with chronic GERD and three or more other risk factors.22 The American College of Gastroenterology advises screening in patients with symptoms of GERD for more than 5 years and two or more additional risk factors.23 The ISG task force on GERD has recommended endoscopy in patients with longstanding symptoms of GERD. This would help assess the endoscopic severity of GERD, the presence of hiatus hernia, and BE. A population-based approach to identify the high-risk group may not be currently feasible in India due to the lack of community data on the prevalence of BE and the risk of progression to high-grade lesion as well as limitation of resources. However, opportunistic screening among patients visiting health care facilities with long standing reflux symptoms and other risk factors may be a suitable option.

\textbf{Opportunistic detection of BE:} Several endoscopies are performed regularly for various indications among which dyspepsia is perhaps the most common. This provides an excellent opportunity to look for features of BE in these patients as a subset of patients with BE may not have symptoms of GERD. These patients represent another target group for detection of BE.

\textbf{II) Endoscopic detection of Barrett’s Esophagus:} In addition to identifying the high-risk group, a systematic approach to endoscopic examination is essential for detecting BE.24 This includes spending adequate time in inspecting gastroesophageal junction (GE) region, identifying landmarks, and recognizing BE and assessing presence of associated lesions.25 An improper endoscopic assessment without spending adequate time in the examination may be one of the key factors responsible for missing BE in a busy endoscopy practice.

\textbf{a) Detecting BE:} The endoscopic examination begins with cleaning the mucosal surface of mucus/debris. If the patient is restless or retching, sedation may be used. On endoscopy, BE appears as a salmon or pink colored mucosa. BE is defined as a distance of more than 1 cm between GE junction and Z line (\textit{Fig. 2}). GE junction is located at the top of gastric mucosal folds. Excessive air insufflation should be avoided as it may flatten the folds. An alternative method to locate the GE junction is by noting the distal limit of palisading vessels in the

\textbf{Fig. 1} Risk factors for development of Barrett’s esophagus.
esophagus. However the inter-observer variation is less-
er for identifying gastric folds than palisading vessels. The Z line denotes the transition point between pale-
ning stratified squamous epithelium of the esoph-
thalmic black arrow - gastroesophageal junction; Blue arrow – Z line (squamocolumnar junction); C – circumferential extent of Barrett’s esophagus; M - maximal extent of Barrett’s esophagus.

III) Improving detection of dysplasia in Barrett’s Esoph-

gus: In a small subgroup of patients, BE progresses to
dysplasia and adenocarcinoma. The rate of progression to
dysplasia or even adenocarcinoma. These areas should
eoscopy is the standard
test to detect BE, its invasive nature has led to the
evaluation of less-invasive tools to detect BE. This
includes devices (non-endoscopic) such as sponges
and balloon to collect cells from the lower esophagus
for assessing cytopathology and the presence of mo-
lar markers of BE. The assessment of markers in
blood (e.g., microRNA) and breath (e.g., volatile organic
compounds) have also shown positive results. These
tools are promising but are still in the stage of develop-
ment. Currently, UGI endoscopy remains the stan-
dard test for detecting BE.

Fig. 2 Whit light image of the lower esophagus showing various
landmarks to be examined for diagnosis and the estimation of extent
of Barrett’s esophagus. Blue arrow – gastroesophageal junction; Black
arrow – Z line (squamocolumnar junction); C – circumferential extent
of Barrett’s esophagus; M - maximal extent of Barrett’s esophagus.

b) Identification of associated lesions: An adequate
endoscopic examination includes assessment for other
findings present along with BE. The presence of hiatus
hernia and its extent should be described. Erosive
esophagitis and its severity should be documented.
Significant esophagitis hampers histological assessment
of BE and dysplasia, and such patients may need a repeat
endoscopic assessment after 8 to 12 weeks of acid
suppressant therapy. One should carefully look for the
presence of nodules/elevated lesions and depressed
lesions within Barrett’s segment as it may be a focus
of dysplasia or even adenocarcinoma. These areas should
be biopsied, and sample sent in a separate container.
A proper endoscopic assessment is crucial to detect BE
as well as avoid overdiagnosis. A < 1 cm segment of
columnar metaplasia carries a very low risk of malign-
nancy, and most societies recommend against biopsy
and diagnosing BE in them to avoid unnecessary anx-
ity among patients. While endoscopy is the standard
test to detect BE, its invasive nature has led to the
evaluation of less-invasive tools to detect BE. This
includes devices (non-endoscopic) such as sponges
and balloon to collect cells from the lower esophagus
for assessing cytopathology and the presence of mo-
lar markers of BE. The assessment of markers in
blood (e.g., microRNA) and breath (e.g., volatile organic
compounds) have also shown positive results. These
tools are promising but are still in the stage of develop-
ment. Currently, UGI endoscopy remains the stan-
dard test for detecting BE.

III) Improving detection of dysplasia in Barrett’s Esoph-

gus: In a small subgroup of patients, BE progresses to
dysplasia and adenocarcinoma. The rate of progression to
eAC increases from the group with “no dysplasia” (0.2–
0.4% per year) to LGD (1–2% per year) and HGD (4–8% per
year). The appropriate management of BE depends on the
presence of dysplasia or EAC. Patients with HGD
require endoscopic ablative therapy, while EAC/local le-
sion may be managed with endoscopic removal or sur-
gery. Patients with LGD need endoscopic surveillance
every 6 to 12 months and more recently they are also
being treated with ablative therapy. Patients with BE
without dysplasia should be kept on endoscopic surveil-
ance every 3 to 5 years. Hence, dysplasia detection is
the key to select appropriate therapy. An important
limitation of the four-quadrant random biopsy (Seattle
protocol) is that it samples a very small surface area of
mucosa (3–4% surface area) and may miss dysplasia if the
dysplastic area is not sampled during biopsy. The compli-
ance of endoscopists with the biopsy protocol may also be
affected due to the time taken for biopsies and patient
discomfort especially in those with long-segment BE.

A proper endoscopic assessment is crucial to detect BE
be biopsied, and sample sent in a separate container.

Table 2

<table>
<thead>
<tr>
<th>BE Segment</th>
<th>Maximal Extent</th>
<th>Circumferential Extent</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt; 3 cm</td>
<td>M</td>
<td>C</td>
</tr>
<tr>
<td>1–3 cm</td>
<td>M</td>
<td>C</td>
</tr>
<tr>
<td>&lt; 1 cm</td>
<td>M</td>
<td>C</td>
</tr>
</tbody>
</table>

Digital chroendo: This technology uses
digital manipulation of the wavelength of light to
highlight the surface characteristics of the mucosa (micro surface). In addition, they also highlight the vascular pattern, which is an advantage over dye-spray chromoendoscopy. They increase the detection rate of dysplasia in BE by ~30%. Available technologies include narrow band imaging (NBI, Olympus), blue light imaging (BLI, Fujinon) and i-scan (Pentax). Among them, the largest number of research publications have been on the use of NBI in detecting dysplasia in BE. The surface pattern in BE may be of different types including ridge pattern, tubular pattern, villous pattern, cerebriform/gyrate pattern, or circular/oval pattern. The vessels may be in the honeycomb pattern, situated between mucosal ridges or appear as regularly branched structures. Hence, there is no single specific pattern for BE on digital chromoendoscopy. The main advantage lies in the detection of dysplasia/neoplasia in real time and taking targeted biopsy from the dysplastic/neoplastic area during endoscopy. –Fig. 3 shows the image of BE obtained by NBI and there is a regular pattern of microvessels and microsurface suggesting the absence of HGD. In this situation, the usual random four quadrant biopsy is sufficient. However, in –Fig. 4, one area (arrow) shows irregular microvascular pattern suggestive of HGD and this area should be targeted for biopsy in addition to the four-quadrant biopsy.

The interpretation of images on NBI requires training but is not very difficult and a randomized study showed similar efficacy of classroom teaching versus self-directed learning. Several classification systems have been proposed to identify dysplasia on NBI or other techniques. The common theme across all these classifications is identifying irregularity in the surface and/or vascular pattern as a marker of dysplasia. The BING (Barrett’s international NBI group) classification is one of the simple classifications for detecting dysplasia. The presence of a regular mucosal surface pattern (ridge villous, tubular or circular) and regular vascular pattern (vessels situated regularly along or between mucosal ridges) excludes dysplasia with an accuracy of 85%. Irregularity of vascular and/or surface pattern suggests the presence of dysplasia. More recently, the Japanese experts have refined the BING classification (BING-J) to further elaborate the description of “flat pattern.” This is described as a completely flat surface with no clear demarcation line and containing greenish thick vessels. This appearance is suggestive of non-dysplastic area. The performance of NBI in detecting HGD has been evaluated in a meta-analysis that showed a sensitivity of 96% and specificity of 94%.

**b) Dye-spray chromoendoscopy:** This involves the spray of a dye on the mucosal surface to highlight the abnormal areas. Among these techniques, acetic acid spray chromoendoscopy has shown the best results in detecting dysplasia in BE. Spray of dilute acetic acid (2.5%) results in a change in the color of BE segment from salmon/pink to snow white.

<table>
<thead>
<tr>
<th>Techniques</th>
<th>Examples</th>
</tr>
</thead>
<tbody>
<tr>
<td>Digital chromoendoscopy</td>
<td>Narrow band imaging</td>
</tr>
<tr>
<td></td>
<td>Blue light imaging</td>
</tr>
<tr>
<td></td>
<td>i-scan (Pentax)</td>
</tr>
<tr>
<td>Chemical spray</td>
<td>Acetic acid</td>
</tr>
<tr>
<td></td>
<td>Methylene blue</td>
</tr>
<tr>
<td>Endomicroscopy</td>
<td>Confocal laser endomicroscopy</td>
</tr>
<tr>
<td></td>
<td>Endocytoscopy</td>
</tr>
<tr>
<td>Cross-sectional imaging</td>
<td>Volumetric laser endomicroscopy</td>
</tr>
</tbody>
</table>

---

**Table 2** Endoscopic techniques for real time detection of dysplasia in Barrett’s esophagus

**Fig. 3** Narrow band imaging of Barrett’s esophagus showing regular microsurface and microvascular pattern. These features suggest the absence of high-grade dysplasia or neoplasia.

**Fig. 4** Narrow band imaging of Barrett’s esophagus showing a focal area with irregular microvascular pattern (arrow). This suggests the presence of high-grade dysplasia in this area.
(acetowhitening). Focal loss of acetowhitening is a strong predictor of dysplasia/neoplasia. In addition, surface characteristics such as irregularity, increased density, and absent pits have also been observed in advanced lesions. These features have been incorporated in a classification (PREDICT) and shown to have good performance in detecting HGD/EAC in Barrett’s esophagus. Acetic acid has the advantage of being cheap and can be easily procured. Another agent for dye-spray chromoendoscopy in BE is methylene blue. It is taken up by absorptive cells (intestine) but not gastric or esophageal epithelium. BE with intestinal metaplasia takes up the stain. In the presence of dysplasia or EAC, staining may be reduced and heterogeneous. This technique can help identify dysplastic areas in BE although a meta-analysis did not show this technique to be superior to random biopsy.

c) Other techniques: Techniques such as confocal laser endomicroscopy and endocytoscopy provide highly magnified image of the epithelium and enable visualization of cellular and subcellular structures in real time (in vivo histology). They can identify columnar epithelial cells and goblet cells and nuclear abnormalities, suggestive of dysplasia or cancer. Another technique that has shown promising result in detecting dysplasia in BE is volumetric laser endomicroscopy. This provides a high-resolution cross-sectional image of mucosal microstructure, and a 6 cm area can be scanned within 90 seconds to a depth of 3 mm. Molecular imaging to identify abnormally expressed genes by fluorescent probes is also being developed for the detection of dysplasia. While these technologies are promising, they are limited by the cost, interpretation of images, and availability.

An adjunctive technology to four quadrant random biopsy is the wide area trans-epithelial sampling (WATS-3D, CDx Diagnostics, NY). The surface of BE is scraped by a brush and cells are placed into a liquid medium. Atypical cells are identified by artificial intelligence-based system for further evaluation by pathologist. This technique aims to cover a wider area of BE to reduce the sampling error. Along with the use of newer technologies, spending more time on examination has also shown to improve the detection of high-grade lesions. An important practical challenge in the application of newer technologies is the need for familiarity and training on the appearance of nondysplastic and dysplastic mucosa. This can be potentially overcome by the development of artificial intelligence systems to help with image interpretation. There has been a rapid pace of research in this area and the results so far are very promising.

Practice Recommendations: For the primary detection of BE, a good WLE with four quadrant biopsies in patients with salmon/pink color mucosa extending for >1 cm above GE may be sufficient. This holds true for both high-risk group as well as patients who are undergoing endoscopy for other indications. Hence, the availability of IEE should not impact detection of BE. Spending adequate time in the examination is crucial. The key benefit of IEE is in detecting dysplasia. In patients with a diagnosis of BE, endoscopy for the detection of dysplasia should preferably include chromoendoscopy. In centers with IEE facilities (equipment and expertise), they should be used for real-time identification of dysplasia and targeted biopsy. In centers without IEE facilities, acetic acid spray is a suitable alternative as it is cheap and has shown good performance in detecting dysplasia in BE. The use of sedation may further facilitate proper examination by keeping the patient comfortable.

In conclusion, BE is not uncommon in Indian patients with GERD. The detection of BE may be improved by identifying the high-risk group and performing adequate and systematic examination during endoscopy. Among the tools for detection of dysplasia, image-enhanced endoscopy or acetic acid-based chromoendoscopy appear to be suitable options currently. The creation of multi-center national registry to collect data prospectively on patients with BE including

---

Table 3 Image-enhanced endoscopy to detect dysplasia in Barrett’s mucosa: suggested steps

- Ensure patient comfort. Use sedation as required.
- Attach a cap (soft, transparent, or black) to the distal end of the endoscope.
- Clean the mucosal surface of mucus, debris, etc.
- Begin with a proper assessment of Barrett’s mucosa with white light examination. Look for elevated or depressed areas, ulcers, etc.
- Switch to image-enhanced endoscopy. Assess the microsurface pattern in the area with Barrett’s esophagus. Look for irregularity of microsurface pattern.
- Assess the microvascular pattern in the area with Barrett’s esophagus. Look for irregularity of the microvascular pattern.
- After assessment of entire Barrett’s mucosa with image-enhanced endoscopy including any abnormal areas seen on white light endoscopy, proceed to mucosal biopsy.
- If irregularity is noted on the microsurface pattern or microvascular pattern, then suspect dysplasia/neoplasia and take targeted biopsy from the site (only one to two bits to avoid fibrosis that may hamper future endoscopic resection/dismemberment). In addition, four quadrant biopsy should be taken according to the Seattle protocol.
- If there are no irregularity of microsurface or microvascular pattern, proceed to four quadrant biopsy according to the Seattle protocol.
follow-up will enable us to understand the magnitude of this condition, frequency of dysplasia, and the risk of progression to cancer. This would make the role of surveillance clearer among our patients and help formulate appropriate management guidelines.

Funding
None.

Conflict of Interest
None declared.

References
2. Marques de Sá I, Pereira AD, Sharma P, Dinis-Ribeiro M. Systematic review of the published guidelines on Barrett's esophagus: should we stress the consensus or the differences? Dis Esophagus 2020;doaa115
13. Wani IR, Showkat H, Bhargav DK, Samer M. Prevalence and risk factors for Barrett’s esophagus in patients with GERD in Northern India; do methylene blue-directed biopsies improve detection of Barrett’s esophagus compared the conventional method? Middle East J Dig Dis 2014;6(04):228–236
26. Amano Y, Ishimura N, Furuta K, et al. Which landmark results in a more consistent diagnosis of Barrett’s esophagus, the gastric folds or the palisade vessels? Gastrointest Endosc 2006;64(02):206–211
Improving detection of Barrett’s esophagus in India

Dutta


48 Gupta N, Gaddam S, Wani SB, Bansal A, Rastogi A, Sharma P. Longer inspection time is associated with increased detection of high-grade dysplasia and esophageal adenocarcinoma in Barrett’s esophagus. Gastrointest Endosc 2012;76(03):531–538

